Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography (PSMA-PET)

November 13, 2026 updated by: Jean-Mathieu Beauregard

PSMA-PET: Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography

The purpose of this study is to make non-approved PSMA radioligands available at CHU de Québec - Université Laval, while assessing their safety. Our hypothesis is that all the PSMA PET radioligand are safe, with a very low incidence of adverse events (AEs). The potential clinical impact of PSMA-PET will be explored in our clinical setting.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

5000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Quebec
      • Québec, Quebec, Canada, G1R2J6

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

1. Reception of a procedure request for PSMA-PET

Exclusion Criteria:

  1. Incapacity to provide informed consent
  2. Pregnancy, unless there has been a discussion between the participant and a nuclear medicine physician investigator about the potential clinical benefits vs. the potential risks for the fetus, in the context of the participant's medical condition, and that this discussion is documented in the nuclear medicine physician's clinical report.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PSMA-PET

Administration of a PSMA tracer for PET

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of Participants with PSMA PET radiopharmaceuticals-Related Adverse Events as Assessed by CTCAE v5.0 .
Time Frame: up to 1 week
up to 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jean-Mathieu Beauregard, MD, CHU de Quebec (Université Laval)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 4, 2021

Primary Completion (Estimated)

December 31, 2031

Study Completion (Estimated)

December 31, 2032

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe